Purpose-built to meet growth in clinical trial services business
PCI has completed its new North American storage and distribution facility for clinical trial materials. The 97,000ft2 purpose-built site was constructed in support of the growth that the company has experienced in its clinical trial services business, which includes drug development and manufacturing, laboratory services, packaging and storage services, global logistics, as well as client supporting consultative services for executing global investigational studies.
PCI offers these services at facilities across North America and Europe, and distributes clinical trial supplies through a network of global depots.
The new facility includes extensive storage for investigational supplies at controlled room temperature, and expands PCI's cold chain storage capacity, including conditions at 2–8°C, -20°C, and -80°C. In addition, the facility is a DEA registered site for Schedule II–V Controlled Substances.
These ongoing investments in our clinical trials business continue to allow us to grow our presence in this market
Special consideration has been given to the management of returned investigational products, an essential service where PCI supports clients by managing investigational study materials returned from clinical trial sites across the globe, including preplanning, on-site processing at receipt, detailed reconciliation, multi-year storage, and certified destruction where necessary. PCI has dedicated more than 8,000ft2 of the new facility for this regulatory segment of the business.
The opening of the facility highlights a significant ongoing investment by PCI in its clinical trial services business. In August, the company acquired Penn Pharma, a leading provider of drug development and drug manufacturing services located in Tredegar, South Wales.
Last month, PCI acquired Biotec Services, located in Bridgend, South Wales. Biotec provides clinical trial services with specialisation in controlled temperature management services ranging from +25°C to -196°C.
With these acquisitions, PCI’s global footprint expands to 16 facilities across North America and Europe.
Bob Misher, Senior Vice President of PCI Clinical Trial Services, said: 'These ongoing investments in our clinical trials business continue to allow us to grow our presence in this market and at the same time keep our focus on the significant importance of each package we prepare and each shipment of investigational study material we manage. It is an exciting time for PCI.'